Nadroparin-induced skin necrosis: clinical manifestation of HIT-2 even in the absence of thrombocytopenia

Diego Luis Carrillo Pérez, Adriana Guadalupe Peña-Romero, José Manuel Díaz-González, Judith Domínguez-Cherit

**DESCRIPTION**

A 33-year-old man with chronic heart failure secondary to dilated cardiomyopathy who developed pneumonia during his stay in the intensive care unit (ICU), was started on subcutaneous nadroparin (2850 UI subcutaneously, once a day) as prophylaxis against venous thromboembolism. By day 7, he had developed a heart-shaped blistering skin lesion with central necrosis and surrounding erythema at the nadroparin injection site (figure 1). Throughout his stay, laboratory tests revealed neither thrombocytopenia nor evidence of systemic thrombosis; but despite this unusual presentation, we clinically suspected a high probability of type II heparin-induced thrombocytopenia (HIT) and a score of 6 points according to the 4T’s HIT scoring system was established. Nadroparin was replaced by dabigatran 150 mg two times a day.

Skin necrosis at the site of heparin injections is a well-described complication of treatment with unfractionated or low-molecular weight (LMW) heparin, and should immediately suggest the presence of HIT. The most common and often first manifestation of HIT is thrombocytopenia, occurring in up to 90% of those affected. Thrombosis occurs in up to 50% of patients, more frequently due to venous than to arterial thrombi (4:1 ratio); thrombosis is the initial finding in up to 25% of patients. Thrombosis can lead to skin necrosis, limb gangrene and organ infarction.

Heparin-induced skin lesions are strongly associated with the formation of HIT-IgG antibodies and should be considered as a manifestation of the HIT syndrome, even in the absence of thrombocytopenia as conventionally defined. Skin lesions occur in 10–20% of patients with HIT. These lesions are due to intradermal microvascular thromboses; however, as in delayed-type hypersensitivity reactions, they begin as erythematous lesions that subsequently lead to cutaneous necrosis, usually with a central black eschar surrounded by indurated erythema. These painful lesions can also develop at a distance from the heparin injection sites, even in the absence of thrombocytopenia.

The paradoxical absence of thrombocytopenia in patients with HIT is especially observed in the ICU setting. Several acute conditions can be associated with thrombocytosis (sepsis, inflammation, trauma, drug side effects, etc), and can mask thrombocytopenia. The most relevant differential diagnoses include calciphylaxis, coumadin-induced necrosis and the antiphospholipid syndrome. The decisive diagnostic procedure in heparin-induced necrosis is HIT antibody testing, histological examination and the chronological connection between the initiation of heparin therapy and the first appearance of skin necrosis; this usually occurs 5–10 days later, either at the site of injection or far from the area of puncture.

**Learning points**

- Skin necrosis at either the heparin injection site or at a distance, should immediately suggest the presence of heparin-induced thrombocytopenia (HIT), with a score of 2 points in the 4T’s scoring system.
- Heparin-induced skin lesions are strongly associated with the formation of HIT-IgG antibodies and should be considered a manifestation of the HIT syndrome, even in the absence of thrombocytopenia.
- In patients with a presumptive diagnosis of HIT, all sources of heparin should be discontinued, and a non-heparin anticoagulant should be administered to decrease the risk of life-threatening thrombosis.

**Figure 1** Heart-shaped skin necrosis and blistering.
REFERENCES

